Ibandronsäure Onkovis (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to bone mineral surfaces and is taken up by osteoclasts during bone resorption. Inside the osteoclast, it interferes with the mevalonate pathway, leading to apoptosis of these cells. The resulting decrease in osteoclast activity reduces bone turnover and helps maintain stronger, more stable bone tissue.

The specific dose and infusion schedule are determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment goals. Ibandronsäure Onkovis is administered intravenously, and the prescriber will decide the appropriate amount and frequency for each individual.

The pregnancy category for ibandronic acid is unknown, and there are no adequate studies in pregnant or lactating women. It should only be used during pregnancy or breastfeeding if the potential benefits justify the potential risks to the fetus or infant. In most cases, alternative therapies are preferred.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain logistics if needed), and the necessary import documentation.

Ibandronsäure Onkovis is similar to other intravenous bisphosphonates such as zoledronic acid, but it is typically given at longer intervals (e.g., every 3 months) due to its high potency and prolonged bone binding. Both agents reduce fracture risk, yet ibandronate may have a slightly lower incidence of acute renal effects, while zoledronate is often used for a broader range of oncologic indications.

The product must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the temperature rises above the recommended range, discard the product to ensure safety and efficacy.

Ibandronsäure Onkovis is given as an intravenous infusion. The healthcare professional prepares the dose according to the prescribing information and administers it over a short period, typically 15‑30 minutes, under medical supervision. Patients are monitored for acute reactions during and after the infusion.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe hypocalcemia, and acute renal impairment. Patients should be educated about these risks, maintain good oral hygiene, report any unusual bone pain promptly, and have renal function monitored before and during treatment.

Ibandronsäure Onkovis is contraindicated in patients with known hypersensitivity to ibandronic acid or any component of the formulation, those with severe renal impairment (creatinine clearance <30 mL/min), uncontrolled hypocalcemia, and in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.